ReviewCurrent drug targets2025
Pharmacological and Therapeutic Potential of a Natural Flavonoid Icariside II in Human Complication.
Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preclinical pharmacological effects of epimedium-derived interventions in osteoarthritis: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Epigenetic Regulation of Ferroptosis in Inflammation: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Natural Combatants: How Herbal Monomers Regulate Autophagy in Ovarian Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Icariside II attenuates renal fibrosis through mTOR signaling modulation: an integrated approach combining network pharmacology, molecular dynamics, andTranslational andrology and urology · 2025Article
- Computational toxicology in drug discovery: applications of artificial intelligence in ADMET and toxicity prediction.Briefings in bioinformatics · 2025Review
- Icariin against osteoporosis: a review of advances in molecular mechanisms to biomedical applications.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging challenges to human health necessitate a coordinated effort to find both preventative and therapeutic techniques, with natural products at the forefront of attempts to gain novel medicines and minimize disease transmission and related death. The medicinal potential of chemicals contained in plants has been known for centuries, leading to its use in homes and clinics for the treatment of numerous disorders. Despite global advancements, plant-based medicines continue to be utilized to treat various pathological illnesses or as alternatives to contemporary pharmaceuticals. The safety and low toxicity of natural products have led to their increasing acceptability for the prevention or treatment of many ailments. Flavonoids are biologically active compounds that are classified as polyphenols, which are a type of secondary metabolite found in all plants. Icariside II (ICA-II) is one of the secondary metabolites that belong to the flavonoid category of phytochemicals and is present in
Indexed as
Identifiers
39757637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.